- Home
- HTCR vs LPCN Comparison
HTCR vs LPCN Comparison
Compare HTCR & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HTCR
- LPCN
- Stock Information
- Founded
- HTCR 2009
- LPCN 1997
- Country
- HTCR Japan
- LPCN United States
- Employees
- HTCR N/A
- LPCN N/A
- Industry
- HTCR EDP Services
- LPCN Biotechnology: Pharmaceutical Preparations
- Sector
- HTCR Technology
- LPCN Health Care
- Exchange
- HTCR Nasdaq
- LPCN Nasdaq
- Market Cap
- HTCR 16.9M
- LPCN 16.1M
- IPO Year
- HTCR 2022
- LPCN N/A
- Fundamental
- Price
- HTCR $0.96
- LPCN $2.98
- Analyst Decision
- HTCR
- LPCN Strong Buy
- Analyst Count
- HTCR 0
- LPCN 2
- Target Price
- HTCR N/A
- LPCN $9.00
- AVG Volume (30 Days)
- HTCR 2.4M
- LPCN 16.5K
- Earning Date
- HTCR 08-13-2025
- LPCN 11-06-2025
- Dividend Yield
- HTCR N/A
- LPCN N/A
- EPS Growth
- HTCR N/A
- LPCN N/A
- EPS
- HTCR N/A
- LPCN N/A
- Revenue
- HTCR $29,625,381.00
- LPCN $4,208,119.00
- Revenue This Year
- HTCR N/A
- LPCN N/A
- Revenue Next Year
- HTCR $3.52
- LPCN N/A
- P/E Ratio
- HTCR N/A
- LPCN N/A
- Revenue Growth
- HTCR 72.95
- LPCN N/A
- 52 Week Low
- HTCR $0.39
- LPCN $2.68
- 52 Week High
- HTCR $3.38
- LPCN $6.17
- Technical
- Relative Strength Index (RSI)
- HTCR 55.00
- LPCN 48.46
- Support Level
- HTCR $0.84
- LPCN $2.87
- Resistance Level
- HTCR $1.15
- LPCN $3.00
- Average True Range (ATR)
- HTCR 0.23
- LPCN 0.10
- MACD
- HTCR -0.02
- LPCN 0.01
- Stochastic Oscillator
- HTCR 24.20
- LPCN 43.78
About HTCR Heartcore Enterprises Inc.
HeartCore Enterprises Inc is a software development company. The company provides software through two business units. The first business unit includes a customer experience management business. The customer experience management platform includes marketing, sales, service, and content management systems, as well as other tools and integrations that enable companies to attract and engage customers throughout the customer experience. It also provides education, services and support to help customers be successful with the CXM Platform. The second business unit, DX division, is a digital transformation business that provides customers with robotics process automation, process mining, and task mining to accelerate the digital transformation of enterprises.
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.